Table 1.

Effects of various therapeutic agents on inflammasome signal pathway after TBI and SCI.

Therapeutic agents	Targets	Potential Mechanism
Canakinumab 64 65	IL-1β	Anti-IL-1β antibody
Ac-FLTD-CMK 66	GSDMD	Inhibits GSDMD cleavage by directly binding to the catalytic region of caspase1, caspase4, caspase 5 and caspase11
VX-740 and VX-765 68, 69 and Parthenolide 70	Caspase-1	Compound act by covalent modification of the catalytic cysteine residue in the active site of caspase-1
MCC950 73/ 3,4-methylenedioxy-β-nitrostyrene (MNS) 76/ glyburide 77/ OLT1177 78/ CY09 79	NLRP3	Blocks the ATPase domain of NLRP3 Inhibits NLRP3 ATPase activity by cysteine modification
A438079 82, 83	P2X7R	Blocks potassium(K+) efflux
BHB 85	Mitochondrial and ROS	Inhibits Drp1 mitochondrial translocation and Prevent ROS generation
CA-074Me 51, 86	Cathepsin B	Inhibits cathepsin B